Patients From trial design for patients to trial design with patients... At the 2022 Drug Information Association (DIA) annual meeting last week, it was
Views & Analysis A healthy discussion on funding tomorrow’s treatments The adage 'do more with less' is of increasing relevance to global economies, with governments under pressure to cut and compress public spend yet simultaneously increase both productivity and
Views & Analysis Precision medicine and data science: the ‘new normal’ for dr... Balancing innovation and huge unmet patient need with burgeoning cost constraints.
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
